Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
105
Recruiting, any sponsor type, condition "atopic dermatitis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting105
- Completed741
105 trials
Showing 1 to 25, recently updated first.
University of California, San DiegoAcademic, hospital or other
NCT05938478 · 900 participants (planned) · Start Dec 8, 2022 · Primary completion Nov 30, 2034
Drug: Tralokinumab · For: Atopic Dermatitis; Eczema
Sites: La Jolla, California
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07262983 · 20 participants (planned) · Start Nov 25, 2026 · Primary completion May 1, 2030
Drug: baricitinib · For: Hyper IgE Syndrome From STAT3 Mutation; Job s Syndrome; HIES and 2 more
Sites: Bethesda, Maryland
- A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Inmagene LLCIndustry
NCT07037901 · 405 participants (planned) · Start Jun 17, 2025 · Primary completion Dec 2027
Drug: IMG-007; Placebo · For: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema
Sites: Lancaster, California; Los Angeles, California; Ocala, Florida · 33 sites in all
University of MichiganAcademic, hospital or other
NCT05268107 · 30 participants (planned) · Start Jan 25, 2023 · Primary completion Jul 2027
Drug: Dupilumab · For: Atopic Dermatitis
Sites: Ann Arbor, Michigan
- Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPivotal-lookingRecruiting
EHL Bio Co., Ltd.Industry
NCT07377838 · 286 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 2029
Drug: ADSTEM Inj.; Placebo · For: Atopic Dermatitis
Sites: Cheonan, South Korea
- Effects of Treatments on Atopic DermatitisPivotal-lookingRecruiting
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
NCT01631617 · 130 participants (planned) · Start Sep 18, 2012 · Primary completion Jan 1, 2027
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ); Cephalexin and 1 more · For: Eczema; Dermatitis; Skin Diseases, Genetic and 2 more
Sites: Bethesda, Maryland
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07765888 · 375 participants (planned) · Start Aug 17, 2026 · Primary completion Mar 10, 2028
Drug: Tilrekimig; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 23 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07604324 · 63 participants (planned) · Start Jun 2, 2026 · Primary completion Jan 27, 2028
Drug: DCY636; Placebo · For: Dermatitis, Atopic
Sites: Fukuoka, Japan
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisPivotal-lookingRecruiting
LEO PharmaIndustry
NCT06311682 · 195 participants (planned) · Start Jun 10, 2024 · Primary completion Oct 16, 2026
Drug: Tralokinumab + TCS; Placebo + TCS · For: Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; Palo Alto, California · 72 sites in all
- First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07527923 · 160 participants (planned) · Start May 22, 2026 · Primary completion Aug 14, 2028
Drug: REGN20423 · For: Healthy Volunteer; Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; West Hills, California · 9 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07783425 · 1,375 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 8, 2028
Drug: Tilrekimig; Dupilumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 50 sites in all
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisPivotal-lookingRecruiting
Arcutis Biotherapeutics, Inc.Industry
NCT07916480 · 415 participants (planned) · Start Oct 30, 2026 · Primary completion Apr 27, 2028
Drug: Roflumilast Cream 0.3%; Vehicle Cream · For: Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema)
Sites: Birmingham, Alabama; Bryant, Arkansas; Miami Lakes, Florida · 4 sites in all
- FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06564389 · 119 participants (planned) · Start Nov 5, 2024 · Primary completion Jun 2, 2027
Drug: PF-07832837 · For: Healthy Participants; Atopic Dermatitis
Sites: Anaheim, California; San Diego, California; Miami, Florida · 8 sites in all
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06807281 · 450 participants (planned) · Start Dec 2, 2025 · Primary completion Feb 22, 2032
Drug: Abrocitinib · For: Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; San Diego, California · 40 sites in all
- A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07216027 · 165 participants (planned) · Start Nov 20, 2025 · Primary completion Feb 2, 2028
Drug: PF-08049820; Placebo · For: Atopic Dermatitis; Eczema, Atopic
Sites: Phoenix, Arizona; Scottsdale, Arizona; Huntington Beach, California · 52 sites in all
Zai Lab (Shanghai) Co., Ltd.Industry
NCT07235384 · 84 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 28, 2027
Drug: ZL-1503; Placebo and 2 more · For: Atopic Dermatitis (AD)
Sites: Woolloongabba, Australia; Carlton, Australia; Beijing, China · 14 sites in all
Apogee Therapeutics, Inc.Industry
NCT07003425 · 350 participants (planned) · Start May 14, 2025 · Primary completion Dec 2029
Drug: APG777; APG777 and 1 more · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; Coral Gables, Florida · 80 sites in all
Arjil Pharmaceuticals LLCIndustry
NCT07914088 · 40 participants (planned) · Start Oct 21, 2026 · Primary completion Dec 30, 2027
Drug: 0.5% AR100DP1 · For: Dermatitis Atopic
Sites: Taipei, Taiwan; Taoyuan, Taiwan
- Cardamom and Topical Roseomonas in Atopic DermatitisPivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06096857 · 120 participants (planned) · Start Oct 9, 2024 · Primary completion Jan 1, 2027
Drug: Roseomonas mucosa (RSM2015) and Cardamom seeds; Placebo (sucrose) · For: Atopic Dermatitis; Eczema
Sites: Bethesda, Maryland
- ADBest TREAT RegistryRecruiting
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT07904546 · 5,000 participants (planned) · Start Jan 1, 2023 · Primary completion Dec 31, 2032
Drug: Abrocitinib; Baricitinib and 5 more · For: Atopic Dermatitis
Sites: Hamburg, Germany
Triveni BioIndustry
NCT07782333 · 90 participants (planned) · Start Sep 9, 2026 · Primary completion Aug 2027
Drug: TRIV-573; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; Boca Raton, Florida · 17 sites in all
Prana Therapies IncIndustry
NCT07810777 · 39 participants (planned) · Start Sep 17, 2026 · Primary completion Sep 30, 2027
Drug: Active PRA-216; Placebo · For: Atopic Dermatitis (AD)
Sites: Botany, Australia; Liverpool, Australia; Coorparoo, Australia · 9 sites in all
- Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic DermatitisPivotal-lookingRecruiting
TRex Bio, Inc.Industry
NCT06934252 · 115 participants (planned) · Start May 2, 2025 · Primary completion Sep 2, 2027
Drug: TRB-061; TRB-061 and 2 more · For: Moderate-to-severe Atopic Dermatitis
Sites: Deakin, Australia; Albion, Australia; Blacktown, Australia · 19 sites in all
- Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Industry
NCT07895615 · 160 participants (planned) · Start Oct 2026 · Primary completion Jan 2028
Drug: LT-002-158 · For: Atopic Dermatitis (AD)
Sites: Hangzhou, China
- Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234Pivotal-lookingRecruiting
Arcutis Biotherapeutics, Inc.Industry
NCT07453602 · 125 participants (planned) · Start Mar 2, 2026 · Primary completion Apr 2028
Drug: ARQ-234; Placebo · For: Atopic Dermatitis (AD); Eczema
Sites: Miami, Florida; Plainfield, Indiana; Fair Lawn, New Jersey · 7 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.